Raj Chakraborty, MD

Raj Chakraborty, MD, is an assistant professor of medicine specializing in hematology/oncology at Columbia University Irving Medical Center. He obtained his medical degree from the University of Delhi, India, and completed his residency in internal medicine at the Icahn School of Medicine at Mount Sinai Queens. Prior to joining Columbia University, he conducted clinical research on plasma cell disorders at the Mayo Clinic, Rochester, and then he pursued a fellowship in hematology/oncology at the Cleveland Clinic. His research interests include clinical trials and outcomes research related to multiple myeloma and light chain amyloidosis. He has published his research findings in esteemed journals such as Blood, Leukemia, and The Lancet Haematology.

Articles by Raj Chakraborty, MD

Aaron Gerds, MDBlood Cancer Talks | July 31, 2024
Dr. Gerds joins the podcast to discuss how he treats patients with polycythemia vera in his practice.
Listen Now
Raj Chakraborty, MDBlood Cancer Talks | July 30, 2024
Dr. Iacoboni joins the podcast to highlight key abstracts from the 2024 ASCO and EHA meetings.
Raj Chakraborty, MDBlood Cancer Talks | July 30, 2024
Benjamin Derman, MD, and Manni Mohyuddin, MBBS, look at how MRD factors into clinical decision-making in this disease.
Raj Chakraborty, MDBlood Cancer Talks | July 30, 2024
Ayalew Tefferi, MD, gives his assessment of clinical trials in myelofibrosis and describes his own management approaches.
Raj Chakraborty, MDMyeloma | November 14, 2022
Raj Chakraborty, MD, discusses how new research on treatments for multiple myeloma may impact the treatment landscape.
Raj Chakraborty, MDMyeloma | November 14, 2022
Raj Chakraborty, MD, speaks about the benefits of antibody drug conjugates (ADC) for multiple myeloma.
Raj Chakraborty, MDMyeloma | November 14, 2022
Raj Chakraborty, MD, speaks about considerations for selecting between BiTEs and CAR T-cell therapy.
Raj Chakraborty, MDMyeloma | November 14, 2022
Raj Chakraborty, MD, speaks about promising results from current clinical trials for newly diagnosed multiple myeloma.